YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now availabl…
By John Vandermosten, CFA OTCQB: RVPH READ THE FULL RVPH RESEARCH REPORT Reviva Pharmaceutical Holdings, Inc. (OTCQB: RVPH) reported first quarter 2026 results following the announcement of the implementation of a new strategy intended to…
Gainers Quantum Cyber (NASDAQ:QUCY) shares rose 163.0% to $0.85 during Wednesday's regular session. The market value of their outstanding shares is at $4.0 million. Whitehawk Therapeutics (NASDAQ:WHWK) stock moved upwards by 29.59% to $5.0…
U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 200 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.49% to 49,515.22 while the NASDAQ gained 0.13% to 26,121.77. The S&P 5…
Gainers Quantum Cyber (NASDAQ:QUCY) shares increased by 55.0% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 21.26% t…
Bristol Myers’ BMY schizophrenia drug Cobenfy delivered a sound performance in 2025. Cobenfy (xanomeline and trospium chloride), formerly KarXT, is an oral medication. It represents the first new pharmacological approach to treat schizophr…
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) earns a place on our top 10 stocks under $5 that could triple.Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split As of March 19, 2026, 8…
(RTTNews) - Reviva Pharmaceuticals Holdings, Inc. (RVPH), a late-stage biopharmaceutical company, saw its shares rise by more than 6% in the pre-market after announcing the closing of its previously announced $10 million public offering on…
(RTTNews) - Reviva Pharmaceuticals Holdings, Inc. (RVPH), a late-stage biopharmaceutical company, priced its previously announced public offering for the sale of 6.66 million shares, together with series G warrants to purchase up to 6.66 m…
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in th…
(RTTNews) - Reviva Pharmaceuticals Holdings, Inc. (RVPH) saw its shares plunge more than 42% overnight after announcing a proposed public offering of common stock and warrants. The company said all securities in the offering would be sold…
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in th…
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is one of the stocks under $1 that will explode.Reviva Pharmaceuticals Holdings (RVPH) Records 37% in 2026 So far As of the market open on January 9, 2026, Reviva Pharmaceuticals Holdings…
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the…
(RTTNews) - Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced that the U.S. FDA has recommended the initiation of a second Phase 3 trial RECOVER-2 for Brilaroxazine before submitting a New Drug Application for the treatment of schizop…
(RTTNews) - Several small-cap biotech and healthcare stocks posted notable gains in after-hours trading on Friday, November 28, 2025, despite limited fresh news flow. Below is a roundup of the key movers. BioAtla Inc. (BCAB) shares surged…
* Reviva Pharmaceuticals press release [https://seekingalpha.com/pr/20307320-reviva-reports-third-quarter-2025-financial-results-and-recent-business-highlights] (RVPH [https://seekingalpha.com/symbol/RVPH]): Q3 GAAP EPS of -$0.06. * As of…
– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilarox…
CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the…
(RTTNews) - Biotech stocks led the after-hours charge on Thursday, with Inhibrx Biosciences (INBX) skyrocketing over 81% on positive Phase 2 trial results in chondrosarcoma. Femasys (FEMY), Cingulate (CING), and Community Health Systems (C…
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the…
(RTTNews) - A wave of after-hours activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Belo…
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan C…
(RTTNews) - After-hours trading on Tuesday featured a wave of notable price moves across the biotech and therapeutics space, with several small- and mid-cap names posting sharp gains following clinical updates, strategic announcements, or…
* Reviva Pharmaceuticals (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) announced [https://seekingalpha.com/pr/20238101-reviva-pharmaceuticals-holdings-inc-announces-pricing-of-9-million-public-offering] on Thursday a public offering…
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in th…
* Reviva Pharmaceuticals Holdings (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) on Thursday said it intends to offer shares of its common stock and warrants to purchase shares of common stock in a public offering. * All of the secur…
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in th…
(RTTNews) - Biotech and healthcare stocks continue to respond sharply to progress in clinical trials, regulatory developments, and broader economic indicators. With the Federal Reserve initiating its first rate cut of 2025 and signaling a…
Bristol Myers BMY won FDA approval for xanomelineand trospiumchloride (formerly KarXT), an oral medication for the treatment of schizophrenia in adults, in September 2024. The drug was approved under the brand name Cobenfy. The approval of…
Key Points Net loss (GAAP) narrowed to $6.1 million in Q2 2025, a 22.8% improvement from the prior-year period, driven by reduced research and development spending. No product revenue reported; The company’s clinical-stage focus and cash b…
* Reviva Pharmaceuticals press release [https://seekingalpha.com/pr/20202002-reviva-reports-second-quarter-2025-financial-results-and-recent-business-highlights] (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]): Q2 GAAP EPS of -$0.12 i…
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized dou…
* Reviva Pharmaceuticals Holdings (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) on Thursday announced the pricing of its public offering with existing and new healthcare focused institutional investors. * The offering entails the pu…
CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the…
Investing.com -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) stock tumbled 23.4% after the late-stage pharmaceutical company announced its intention to offer shares of common stock and warrants in a public offering. The company, wh…